EP3347012A4 - Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central - Google Patents
Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central Download PDFInfo
- Publication number
- EP3347012A4 EP3347012A4 EP16845102.9A EP16845102A EP3347012A4 EP 3347012 A4 EP3347012 A4 EP 3347012A4 EP 16845102 A EP16845102 A EP 16845102A EP 3347012 A4 EP3347012 A4 EP 3347012A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- muscarinic
- combinations
- controlling
- nervous system
- central nervous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217081P | 2015-09-11 | 2015-09-11 | |
| US201662351382P | 2016-06-17 | 2016-06-17 | |
| PCT/US2016/050907 WO2017044714A1 (fr) | 2015-09-11 | 2016-09-09 | Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3347012A1 EP3347012A1 (fr) | 2018-07-18 |
| EP3347012A4 true EP3347012A4 (fr) | 2019-04-17 |
Family
ID=58240063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16845102.9A Withdrawn EP3347012A4 (fr) | 2015-09-11 | 2016-09-09 | Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3347012A4 (fr) |
| CA (1) | CA2996719A1 (fr) |
| WO (1) | WO2017044714A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| PL3061821T3 (pl) | 2009-07-22 | 2020-01-31 | PureTech Health LLC | Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego |
| JP7096441B2 (ja) | 2018-09-28 | 2022-07-05 | カルナ セラピューティックス,インコーポレイテッド | ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144719A1 (fr) * | 2015-03-06 | 2016-09-15 | Chase Thomas N | Combinaison d'agoniste des récepteurs muscariniques et d'oxybutynine dans un système thérapeutique transdermique |
| WO2016144749A1 (fr) * | 2015-03-06 | 2016-09-15 | Chase Thomas N | Système thérapeutique transdermique constitué de combinaisons d'oxybutynine et de xanoméline |
| WO2017015349A1 (fr) * | 2015-07-20 | 2017-01-26 | Chase Pharmaceuticals Corporation | Combinaison muscarinique d'un antagoniste sélectif du récepteur m2 et d'un antagoniste non sélectif périphérique pour le traitement de troubles hypocholinergiques |
| WO2017044693A1 (fr) * | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central |
| WO2017147104A1 (fr) * | 2016-02-24 | 2017-08-31 | Chase Pharmaceuticals Corporation | Combinaisons d'antagoniste muscarinique m2 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US20130289019A1 (en) * | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| WO2014039627A1 (fr) * | 2012-09-05 | 2014-03-13 | Chase Pharmaceuticals Corporation | Composition et procédés neuroprotecteurs anticholinergiques |
-
2016
- 2016-09-09 EP EP16845102.9A patent/EP3347012A4/fr not_active Withdrawn
- 2016-09-09 CA CA2996719A patent/CA2996719A1/fr active Pending
- 2016-09-09 WO PCT/US2016/050907 patent/WO2017044714A1/fr not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144719A1 (fr) * | 2015-03-06 | 2016-09-15 | Chase Thomas N | Combinaison d'agoniste des récepteurs muscariniques et d'oxybutynine dans un système thérapeutique transdermique |
| WO2016144749A1 (fr) * | 2015-03-06 | 2016-09-15 | Chase Thomas N | Système thérapeutique transdermique constitué de combinaisons d'oxybutynine et de xanoméline |
| WO2017015349A1 (fr) * | 2015-07-20 | 2017-01-26 | Chase Pharmaceuticals Corporation | Combinaison muscarinique d'un antagoniste sélectif du récepteur m2 et d'un antagoniste non sélectif périphérique pour le traitement de troubles hypocholinergiques |
| WO2017044693A1 (fr) * | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central |
| WO2017147104A1 (fr) * | 2016-02-24 | 2017-08-31 | Chase Pharmaceuticals Corporation | Combinaisons d'antagoniste muscarinique m2 |
Non-Patent Citations (2)
| Title |
|---|
| See also references of WO2017044714A1 * |
| SRAMEK J J ET AL: "THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE IN PATIENTS WITH ALZHEIMER'S DISEASE", JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, vol. 35, 1 January 1995 (1995-01-01), pages 800 - 806, XP000563129, ISSN: 0091-2700 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017044714A1 (fr) | 2017-03-16 |
| EP3347012A1 (fr) | 2018-07-18 |
| CA2996719A1 (fr) | 2017-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3692158A4 (fr) | Thérapies géniques pour troubles lysosomiaux | |
| EP3692075A4 (fr) | Thérapies géniques pour troubles lysosomaux | |
| EP3364993A4 (fr) | Procédés pour traiter le syndrome d'angelman et des troubles associés | |
| EP3692151A4 (fr) | Thérapies géniques pour troubles lysosomaux | |
| EP3104708A4 (fr) | Thérapie cellulaire régénérative pour troubles du système nerveux central (snc) et espt | |
| HRP20210518T1 (hr) | Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava | |
| ZA201806382B (en) | Liquid filter arrangement and methods | |
| MA51075A (fr) | Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine | |
| EP2807412A4 (fr) | Procédés et systèmes de surveillance nerveuse pour le traitement de troubles pharyngés | |
| DE112015004742A5 (de) | Separatorplatte und elektrochemisches System | |
| SG11201607705XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| HUE051488T2 (hu) | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére | |
| EP3243663A4 (fr) | Tête de déversement de liquide, unité de déversement de liquide, et dispositif pour déverser un liquide | |
| HUE054092T2 (hu) | Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások | |
| PL3392931T3 (pl) | Separator dla urządzenia elektrochemicznego i urządzenie elektrochemiczne go zawierające | |
| EP3235470A4 (fr) | Biohybride à utiliser dans la régénération de fibres neuronales | |
| EP3442547A4 (fr) | Thérapies à base de probiotiques pour troubles du développement et autres troubles neurologiques | |
| EP3151205A4 (fr) | Machine tout-en-un à circulation et dispositif de distribution de billets de banque de celle-ci | |
| EP3618824A4 (fr) | Utilisation de n-acétylcystéine pour traiter des troubles du système nerveux central | |
| SG11201608397UA (en) | Glyt1 inhibitors for use in the treatment of hematological disorders | |
| HUE057479T2 (hu) | Szûrõkészülék elválasztólappal | |
| EP3347012A4 (fr) | Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central | |
| SG11201406296SA (en) | Centrifuge having water discharge structure and purifier system using the same | |
| EP3347011A4 (fr) | Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central | |
| EP3463417A4 (fr) | Polythérapies pour la régénération/le remplacement des cellules ciliées sensorielles de l'oreille interne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20180404 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031435000 Ipc: A61K0031216000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20190318 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/454 20060101ALI20190312BHEP Ipc: A61K 45/06 20060101ALI20190312BHEP Ipc: A61K 31/216 20060101AFI20190312BHEP Ipc: A61K 31/517 20060101ALI20190312BHEP Ipc: A61K 31/4439 20060101ALI20190312BHEP Ipc: A61K 31/4178 20060101ALI20190312BHEP Ipc: A61K 9/70 20060101ALI20190312BHEP Ipc: A61P 25/24 20060101ALI20190312BHEP Ipc: A61K 31/166 20060101ALI20190312BHEP Ipc: A61P 25/28 20060101ALI20190312BHEP Ipc: A61P 25/18 20060101ALI20190312BHEP Ipc: A61P 25/00 20060101ALI20190312BHEP Ipc: A61P 25/14 20060101ALI20190312BHEP Ipc: A61K 31/439 20060101ALI20190312BHEP Ipc: A61P 43/00 20060101ALI20190312BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20200623 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230331 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20230310 |